Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01938079 · ClinicalTrials.gov registry record · NA

Pharmacokinetic Alterations During ECMO

A NA study, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT01938079: Completed NA study, sponsored by Columbia University.

NCT01938079 is a NA study that has completed, run by Columbia University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01938079, a NA study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply blood with oxygen. In this case, patients may require assistance from a machine to help provide this oxygen. Extracorporeal membrane oxygenation (ECMO) is a device that acts as an artificial lung, allowing the patient to recover from their illness. Patients receiving support from ECMO are often put in a medically induced coma while their lungs heal. Certain drugs may stick to the internal surfaces of the machine; therefore leading to decreased concentrations. Patients receiving ECMO often require high doses of both pain medications and sedatives in order to provide comfort. Low doses of a drug, ketamine, may help to provide additive effects to pain relief and allow lower doses of other pain medications. The hypothesis is that patients treated with continuous intravenous ketamine, will have lower requirements of other pain medications while receiving ECMO for acute respiratory failure while achieving the desired level of sedation.

Primary Outcome

Culmulative fentanyl equivalents meaning the combination of sedative drug regimen - measured in mg - from ECMO initiation to decision to achieve wakefulness.

Interventions

  • DRUG Ketamine
  • OTHER Sedative drug regimen

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-09
Est. Completion 2015-08
Phase NA
Columbia University

958 total trials

What the finished NCT01938079 record still lists

NCT01938079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.

NCT01938079 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01938079 about?

NCT01938079 is a clinical study titled "Pharmacokinetic Alterations During ECMO". In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply blood with oxygen. In this case, patients may require assistance from a mac...

What is the current status of trial NCT01938079?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-09. Estimated completion is 2015-08.

What interventions are being tested in trial NCT01938079?

The interventions under investigation include: Ketamine (DRUG), Sedative drug regimen (OTHER).

Who is sponsoring clinical trial NCT01938079?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01938079's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01938079, the US trial registry maintained by the National Library of Medicine. NCT01938079 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.